




PHARMACEUTICAL 2023

Tharimmune Inc.
Rank 275 of 446





PHARMACEUTICAL 2023

Tharimmune Inc.
Rank 275 of 446

The relative strengths and weaknesses of Tharimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tharimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Tharimmune Inc. is the variable Net Income, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 16% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,689
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,145
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,591
Other Revenues	0
Property and Equipment	0
Research and Development	2,278
Selling, General and Administrative Expense	4,604

Output Variable	Value in 1000 USD
Assets	6,689
Liabilities	1,145
Expenses	6,882
Revenues	0
Stockholders Equity	5,544
Net Income	-8,473
Comprehensive Net Income	-8,473
Economic Capital Ratio	27%